Veranova Devens Site Breaks Ground on ADC Facility Expansion

June 19, 2025

Devens, MA, USA — Government officials, industry leaders, and local business representatives gathered yesterday to mark the groundbreaking of Veranova’s latest expansion at its Devens, Massachusetts facility.

First announced in June 2024, the investment will add 9,000 square feet to the site, including a new state-of-the-art process development laboratory and two current Good Manufacturing Practice (cGMP) suites. These new capabilities will expand the site’s development and production capabilities for potent compounds, ADC linker-payloads, and other complex molecules critical to next generation therapeutics.

Earlier this week, Veranova also announced a complementary investment to establish state-of-the-art bioconjugation development and cGMP manufacturing capabilities at the Devens site. Together, these initiatives represent a more than $50 million commitment to strengthening U.S.-based infrastructure for ADCs and bioconjugates, and are expected to create up to 70 new jobs.

In her remarks at the event, U.S. Congresswoman Lori Trahan (MA-03) emphasized the importance of local job creation and maintaining global competitiveness in advanced pharmaceutical manufacturing.

“The fight to end cancer once and for all depends on trailblazers like Veranova, where innovative work in specialty medications is reshaping treatment options for cancer and rare diseases. Their new facility in Devens will create good-paying jobs, boost economic growth, and bolster the domestic supply of active medical ingredients — ensuring Massachusetts stays at the forefront of health care innovation,” said Congresswoman Trahan.

Mike Riley, CEO of Veranova, highlighted the expansion as a strategic investment in innovation and domestic manufacturing capacity.

“This expansion reflects Veranova’s deep commitment to supporting our partners in the development and manufacture of complex, life-saving therapies,” said Mike Riley, CEO of Veranova. “By enhancing our capabilities in Devens, we’re not only investing in innovation and growth, but also strengthening domestic infrastructure for the production of critical medicines like ADCs and other highly potent compounds.”

Veranova’s Devens site already offers a broad range of services, including cGMP laboratories, clinical and commercial kilo labs, and multi-purpose production suites. Its proximity to the Boston life sciences hub ensures strategic access to one of the world’s most dynamic biotechnology ecosystems.

About Veranova

Veranova is a global leader in process development and manufacturing of APIs, with a focus on specialty and complex chemistry for small molecules, antibody-drug conjugates, oligonucleotides, and peptides. Veranova is headquartered in Devens, Massachusetts, and has operations in North America and Europe.

Contact Details

For further information and interview opportunities with Veranova, please contact:
Charles Ben-Cofie
Senior Content Manager, Notch Communications
T: +44 (0) 161 457 7230
E: charles.ben-cofie@notchcommunications.co.uk